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Abstract
Men and women exhibit significant differences in obesity, cardiovascular disease and diabetes. To 
provide better diagnosis and treatment for both sexes, it is important to identify factors that 
underlie the observed sex differences. Traditionally, sex differences have been attributed to the 
differential effects of male and female gonadal secretions (commonly referred to as “sex 
hormones”), which do substantially influence many aspects of metabolism and related diseases. 
Less appreciated as a contributor to sex differences are the fundamental genetic differences 
between males and females, which are ultimately determined by the presence of an XX or XY sex 
chromosome complement. Here we review the mechanisms by which gonadal hormones and sex 
chromosome complement each contribute to lipid metabolism and associated diseases, and the 
current approaches that are used to study them. We focus particularly on genetic approaches 
including genome-wide association studies in humans and mice, “–omics” and “systems genetics” 
approaches, and unique experimental mouse models that allow distinction between gonadal and 
sex chromosome effects.
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I. Sex and metabolism
a. Why is it important to understand sex differences in metabolism?
The most prevalent diseases in developed countries are cardiovascular disease, diabetes, and 
some forms of cancer (35, 95). The incidence of these diseases increases in the presence of a 
group of risk factors known as the Metabolic Syndrome (MetSyn). MetSyn is defined by the 
presence of three of the following five risk factors: abdominal obesity, elevated triglyceride 
levels, low high density lipoprotein (HDL) cholesterol levels, high blood pressure 
(hypertension), and elevated fasting blood glucose levels (73). Sex differences exist in nearly 
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all of the components of MetSyn (Figure 1). For example, females have evolved specific 
mechanisms to favor adipose tissue storage, whereas mobilization of fat stores tends to be 
more efficient in males (40, 60, 77, 90). Compared to men, women tend to have greater 
insulin sensitivity, and the sexes differ in lipoprotein profiles (30, 85). It has become clear 
that it is critical to understand sex differences in metabolism to optimize prevention, 
diagnosis, and therapeutic intervention for both sexes.
Here we review sex differences in obesity, other components of the MetSyn, and related 
factors such as the gut microbiome, with an emphasis on the genetic mechanisms underlying 
these differences. In the sections below, we first discuss the components of sex and 
approaches used to study sex effects. We then review the sex differences in obesity and other 
MetSyn components in humans, and highlight studies in experimental models that shed light 
on the mechanisms involved.
b. Components of sex: gonadal hormones and sex chromosome complement
An understanding of why one sex is more susceptible to specific disease processes requires 
analysis of the component parts of sex. Differences between men and women can be 
influenced by sex and gender. Sex refers to the biological attributes of males and females 
that result from the presence of female (XX) or male (XY) sex chromosomes, which 
ultimately determine the levels and types of gonadal hormones (Figure 2). Gender refers to 
characteristics that a society or culture defines as masculine or feminine. In humans in 
particular, gender may influence behaviors that affect metabolism and related diseases. 
However, gender effects are challenging to assess experimentally and data are lacking on 
their effects on metabolism, and we will therefore limit our review to the biological 
components of sex differences.
The most widely studied sex difference between males and females has been the effect of 
gonadal hormones. In human studies, the contribution of gonadal hormones to a trait of 
interest is often addressed by comparing women before and after the age of menopause, with 
differences between the two attributed to the reduced levels of ovarian hormones after 
menopause. Studies of this sort have demonstrated that post-menopausal women have 
altered body fat distribution and increased incidence of cardiovascular disease, hypertension, 
diabetes and other disorders (41, 68, 74, 122). The levels of androgens also influence 
metabolic disease. Testosterone levels typically diminish in men with age, and low 
testosterone levels in men are associated with increased body fat and cardiovascular disease 
(3, 12, 99). However, these studies are confounded by the fact that the pre- and post-
menopausal (or high and low testosterone) groups usually constitute different individuals 
due to the difficulty of performing longitudinal studies for several years in humans, and 
comparisons between groups could therefore be influenced by genetic and environmental 
heterogeneity. Studies in humans are also complicated by the fact that reductions in gonadal 
hormone levels in older men and women cannot necessarily be distinguished from 
independent changes associated with aging.
In addition to gonadal hormones, sex chromosome complement could contribute to sex 
differences in metabolic traits (8, 69). It has been difficult to address whether hormone-
independent effects of gonadal sex occur in humans because, typically, XX chromosomes 
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and ovaries occur together, and XY chromosomes and testes occur together (Figure 2). Some 
studies of metabolic factors have been performed on individuals with sex chromosome 
anomalies (Turner syndrome or Klinefelter syndrome), and have reported increased 
adiposity and other features of MetSyn (13, 14, 19). However, it is difficult to tease apart the 
role of sex chromosome complement from gonadal hormones in these individuals because 
the alterations in chromosome complement occur in concert with abnormal hormones levels. 
Individuals with Turner syndrome (45, XO) have low endogenous levels of ovarian 
hormones such that it is impossible to distinguish the effects of the single X chromosome 
from those resulting from abnormal ovarian hormone levels (44, 48). Furthermore, Turner 
syndrome subjects often have congenital heart defects, which lead to heart disease 
independent of MetSyn (31). Individuals with Klinefelter syndrome (47, XXY) have reduced 
endogenous androgen levels and are often treated with exogenous androgens, which makes it 
difficult to distinguish effects of the XXY chromosome complement from those of the 
altered androgen levels (53). In addition to the factors outlined above, the interpretation of 
metabolic disease traits in Turner and Klinefelter subjects has been limited by small 
available cohort sizes that preclude meaningful conclusions about metabolic parameters.
c. Approaches to study sex differences
To overcome some of the limitations in studying the components of sex effects in humans, 
experimental animal models are valuable; unique genetic tools in the mouse make it a 
particularly useful animal model. Unlike humans, inbred mice allow an analysis of high and 
low gonadal hormone levels on the identical genetic background. The action of gonadal 
hormones can be classified into two temporal classes: the permanent effects of gonadal 
hormones that lead to the development of sex differences during fetal and neonatal 
development, and the acute actions of gonadal hormones that cause specific responses on 
numerous processes throughout life. The acute effects of gonadal hormones are reversible, 
and a standard way to identify acute hormone effects is to compare adult mice with intact 
gonads to those from which gonads were removed in adulthood. Those sex differences that 
are caused by acute hormonal effects will be abolished in gonadectomized mice, whereas 
sex differences resulting from the permanent effects of gonads during development will 
remain.
The origin of male and female gonads and the hormones that they produce traces back to the 
presence of either XX or XY sex chromosomes (Figure 2). Furthermore, at a more 
fundamental level than hormone action, simply the presence of either XX or XY 
chromosomes leads to sex differences at the cellular level because of the differential action 
of genes on the X and Y chromosomes (7). For example, during early embryonic growth 
prior to the presence of gonads or gonadal hormones, male embryos are larger than female 
embryos in mice, humans, and several other mammals (16). In the mouse, these differences 
have been attributed to a combination of effects from the presence of the Y chromosome in 
male embryos and the sexual imbalance between the number of X chromosomes in males vs. 
females (17, 18). Following differentiation of the gonads, it is difficult to cleanly separate 
effects due to hormones from those resulting from the sex chromosome complement. This 
led to the generation of mouse models that allow the independent segregation of gonadal 
type from sex chromosome complement.
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The most widely used model to distinguish gonadal and chromosome sex effects is known as 
the Four Core Genotypes (FCG) mouse model (Figure 3). This model generates mice having 
XX chromosomes on both male and female gonadal backgrounds and XY mice on male and 
female gonadal backgrounds (4–6). This is accomplished by using a Y chromosome from 
which the testis-determining Sry gene has been deleted. Inheritance of the Sry-deleted Y 
chromosome fails to specify male gonads, and female gonads develop instead, allowing 
production of XY female mice. In addition, an Sry transgene is inserted into chromosome 3, 
such that it segregates independently of the sex chromosomes (56). Inheritance of the Sry 
transgene, even in the presence of XX sex chromosomes, results in development of male 
gonads. The FCG model is valuable to identify whether sex differences in a trait of interest 
are associated with gonadal type or sex chromosome complement (Figure 4). For example, if 
a trait is influenced by gonadal sex, male mice with XX or XY chromosomes will be similar, 
but differ from female mice with XX or XY chromosomes. However, if a trait is influenced 
by sex chromosome complement, XX female and male mice will be similar to one another, 
but differ from XY female and male mice (Figure 4). This model also allows the detection of 
interactions between gonadal hormones and chromosomal sex, and the effects of acute 
hormones can be assessed by comparing gonadally intact with gonadectomized mice, as 
described above. This model has revealed that sex differences in obesity, lipid levels, fatty 
liver, glucose homeostasis and other metabolic traits are influenced by XX vs. XY 
chromosome complement (Figure 5; described in later sections).
II. Genetic contributions to sex differences in adiposity and obesity
a. Sex-specific obesity loci
The heritability of obesity is estimated to be about 50–70%, indicating that genetics play a 
large role in fat accumulation (reviewed in 38). Recently, large-scale genome-wide 
association studies (GWAS) have identified loci linked to fat accumulation and distribution. 
A large meta-analysis of 32 GWAS, with a follow-up of 16 loci in 29 additional studies, 
identified 14 genome-wide significant loci that were associated with waist-to-hip ratio, a 
proxy for adipose distribution (50). In sex-specific meta-analyses, 12 of these 14 single-
nucleotide polymorphisms (SNPs) were significant in women, while only three SNPs were 
significant in men. The 14 loci collectively explained 1.34% of the waist-to-hip ratio 
variance in women and 0.46% of the variance in men. Subsequent studies confirmed these 
loci in genome-wide associations with subcutaneous and visceral adipose tissue measured by 
CT scan (37, 104). When sex-stratified studies were performed, the reported loci had 
statistically significant associations with fat distribution in women, but not in men. 
Concordant with these findings, another large meta-analysis of nearly 225,000 individuals 
reported 49 loci associated with waist-hip ratio adjusted for body mass index, and 20 of 
these 49 loci had significant sexual dimorphism (103). 19 out of 20 sexually dimorphic loci 
had a larger effect in women than in men. Taken together, these GWAS findings highlight 
the importance of performing sex-stratified GWAS to better understand genetic contributors 
of adiposity. These findings also emphasize that a large proportion of the genetic 
determinants of obesity in both sexes remain to be identified.
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b. Sex differences in regional adipose tissue deposition
It is well appreciated that there are inherent differences between men and women in fat 
distribution and properties of fat cells within anatomical depots (Figure 1). When 
normalized to waist circumference or to total body fat, men have more visceral adipose 
tissue (fat within the abdominopelvic cavity) than pre-menopausal women (64, 66). Men 
also tend to lose relatively more visceral adipose tissue due to calorie restriction than women 
(63). By contrast, women typically have more subcutaneous adipose tissue (fat underlying 
the dermis) (66). Numerous epidemiological studies have linked increased visceral fat to 
MetSyn, and others have suggested that subcutaneous adipose tissue may even play a 
protective role against glucose dysregulation and other components of the MetSyn (38, 71, 
96, 108). Thus, in the basal state, the greater subcutaneous to visceral adipose tissue 
composition in women may be a beneficial trait relative to MetSyn development.
Beyond sex differences in fat mass and distribution, metabolic differences have been 
identified in adipocyte biology between men and women that ultimately may contribute to 
the likelihood for abdominal obesity that contributes to MetSyn. For example, a comparison 
of adipocytes isolated from the subcutaneous and visceral compartments of abdominal fat in 
healthy women showed that the intraperitoneal adipocytes were 20–30% smaller than those 
from the subcutaneous depot, whereas men exhibit a similar adipocyte size from these two 
areas of abdominal fat (106). This is relevant because larger adipocytes have higher rates of 
lipolysis, are correlated with insulin resistance, and have increased expression of 
proinflammatory adipokines. It is possible that changes in the basal characteristics of 
adipocytes in women with abdominal obesity are highly detrimental and contribute to the 
development of MetSyn.
c. Gonadal hormone signaling effects on adiposity and potential effectors
The mechanisms underlying sex differences in adiposity have been investigated extensively 
in experimental models by manipulating receptors for gonadal hormone signaling. In 
particular, ablation of estrogen and androgen receptors in the brain and peripheral tissues in 
the mouse results in striking metabolic outcomes. For example, knockout of estrogen 
receptor α (ERα) resulted in increased adiposity in both male and female mice (51, 87). 
Knockout of ERα in hypothalamic neurons also lead to dysregulation of energy balance, 
resulting in increased abdominal fat (84, 117). While deficiency of ERα affects both sexes, 
deficiency of androgen receptor results in late-onset obesity only in males (36). Interestingly, 
adipose-specific knockout of androgen receptor causes hyperleptinemia, but not increased 
adiposity. This suggests that androgen receptor is required in adipocytes for normal levels of 
leptin, but not for expansion of fat tissue.
While gonadal hormones have an irrefutable role in shaping and distributing fat, the specific 
mechanisms have not been fully elucidated. One possible mechanism is a role for gonadal 
hormones, along with nutrients and other signals, as cues to signal adipocyte progenitor cells 
to proliferate and/or differentiate. Indeed, ovarian hormones appear to influence fad pad 
expansion in a sex-specific manner (57). In mice fed a high fat diet, adipocyte precursor 
cells proliferate and differentiate into mature adipocytes to a much greater degree than in 
mice fed a standard chow diet, as would be expected. Interestingly, the removal of acute 
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hormonal effects in females by ovariectomy blunts the proliferative capacity of 
preadipocytes in the subcutaneous fat pad, but not the visceral fat pad. These results suggest 
that gonadal hormones affect precursor cells differentially in distinct fat depots. In addition, 
elegant adipose tissue transplant studies revealed that adipocyte precursor cell behavior is 
dictated by the recipient depot, implicating environment rather than cell-intrinsic properties 
as a determinant of fat tissue hyperplasia (57).
Another potential effector of sex hormone effects on adipose tissue depot expansion may be 
the enzyme aldehyde dehydrogenase 1 (Aldh1a1) (119). Deletion of Aldh1a1 abrogated diet-
induced expansion of subcutaneous fat in male and female mice compared to wild-type 
animals. However, compared to the corresponding wild-type mice, visceral fat mass was 
reduced in female but not male Aldh1a1−/− mice. The female-specific reduction in visceral 
fat of Aldh1a1−/− mice was attributed to differential expression of adipose triglyceride 
lipase, which was likely induced by a buildup of retinaldehyde in Aldh1a1−/− females. The 
authors postulate that the retinoic acid produced by Aldh1a1 action may activate retinoic 
acid receptor response elements (such as in the promoter of the PPARγ gene) to a greater 
degree in female compared to male visceral adipose tissue. While this study identified an 
interesting potential role of retinoic acid in mediating sex differences in fat depots, more 
research is needed to understand how sex-biasing factors, such as sex hormones and sex 
chromosomes, interact with retinaldehyde and retinoic acid signaling pathways.
Sex-biasing factors, such as sex hormones and sex chromosomes, likely mediate sexually 
dimorphic traits via changes in gene expression. Thousands of sexually dimorphic genes 
have been identified in adipose tissue by global gene expression analysis in mice (45, 118). 
These genes were enriched in functional categories such as immune response, lipid 
metabolism, and insulin signaling. The mice used in these studies were fed a high fat diet 
(45–47% calories from fat) to increase adiposity, such that some of the observed sexually 
dimorphic gene expression may reflect sex-dependent responses to nutritional excess and the 
ensuing metabolic dysregulation. Interestingly, only about 100 genes were differentially 
expressed between ovariectomized females and gonadally intact females, suggesting that 
most sexually dimorphic genes are not regulated by circulating gonadal hormones (45).
One factor that may contribute to sexually dimorphic gene expression is regulator of sex-
limitation 1 (RSL1), a zinc finger protein that affects the expression of many transcripts in 
liver and adipose tissue. Deletion of Rsl1 in mice results in sex-specific weight gain (61). 
Rsl1−/− females gain significantly more weight compared to wild-type females, while 
Rsl1−/− and wild-type males have equal weight gain on a high fat diet. In addition, Rsl 
deficiency enhanced sexual dimorphism in adipose tissue gene expression compared to wild-
type mice, suggesting that RSL1 normally suppresses sex differences in adipose tissue.
d. Sex chromosome complement influences adiposity
The obesity loci discovered in GWAS studies and the studies from experimental models 
discussed above account for a small proportion of the estimated genetic heritability of 
obesity. The missing heritability may arise from a number of factors, including a lack of 
power to detect combined effects of numerous loci, which individually, may have 
insignificant associations with adiposity traits. In addition, few GWAS reports stratify 
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associations by sex, thus potentially obscuring our understanding of complex diseases. To 
determine genetic causes of sex differences in adiposity, one must consider the fundamental 
definition of sex in a cell: the sex chromosome complement.
In many cases, the X chromosome is not included in GWAS studies, because arrays do not 
have enough X chromosome variants, or because imputation is needed for combined-sex 
studies (116). This practice impedes discovery of novel associations, especially with 
sexually dimorphic traits such as adiposity. There are more than 1,600 coding and hundreds 
of noncoding genes on the X chromosome, which represent greater than 5% of all human 
genes. The number of X chromosomes, the ability to randomly inactivate an X chromosome, 
and X chromosome imprinting are sources of sex differences between females and males 
that reside in each nucleated cell of every tissue.
Mouse models have been used to demonstrate an effect of XX vs. XY chromosome 
complement on fat accumulation and obesity co-morbidities. Chen et al. used the Four Core 
Genotypes mouse model (Figure 3) to distinguish effects of sex hormones from effects of 
sex chromosomes on obesity (21). All genotypes were on an inbred C57BL/6 background, 
ruling out genetic differences besides sex chromosome complement. To remove acute effects 
of circulating hormones, mice were gonadectomized in early adulthood. Mice with two X 
chromosomes, regardless of whether they originally had ovaries or testes, gained nearly 
twice as much fat as mice with X and Y chromosomes (Figure 5). Remarkably, the enhanced 
weight gain in XX mice was observed on a standard chow diet. The weight difference 
between XX and XY mice was amplified by a high fat diet, becoming statistically significant 
after merely 3 days on the diet. The increased obesity in XX mice was associated with 
increased food intake during the light (inactive) phase of the circadian cycle (21, 22). Along 
with increased adiposity, XX mice developed fatty liver and had elevated levels of fasting 
insulin (Figure 5), both of which are co-morbidities of obesity in humans.
The provocative finding that XX mice have greater adiposity than XY mice raised the 
question of whether the effect was due to the presence of two X chromosomes, or to the 
absence of a Y chromosome. To address this, investigators generated mice with XX, XY, XO 
and XXY sex chromosome complements. When body weight of these mice was followed for 
several months following gonadectomy, the XX and XXY mice had greater body weight 
than XY and XO mice (21). Thus, it was the presence of two X chromosomes that drove 
increased body weight, irrespective of inclusion of a Y chromosome. Interestingly, another 
mouse model of altered sex chromosome number also showed increased body weight in 
mice with two X chromosomes compared to those with one X, regardless of the presence of 
a Y chromosome (23).
The studies described above implicate X chromosome dosage as a risk factor for obesity. It 
will be important to further define the mechanisms involved. One hypothesis is that 
increased expression of genes escaping X chromosome inactivation in XX mice may cause 
phenotypic differences between XX and XY mice (21, 69, 70). This can be investigated by 
modulating the dosage of individual genes that escape X chromosome inactivation in cell or 
mouse models to determine effects on downstream gene expression and physiology.
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III. Sex differences in obesity co-morbidities
In this section, we will review sex differences in co-morbidities of obesity that are also 
components of MetSyn. The prevalence of MetSyn varies across world populations, and it is 
clear that it is influenced by ethnicity, sex, age and socioeconomic status (47, 97, 98). The 
prevalence of MetSyn in the U.S. population is similar in age-adjusted men and women 
(34.9% of men, 33.3% of women) (82), but this may differ in other countries (98). The 
combination of components that most often lead to a diagnosis of MetSyn differ between the 
sexes (97, 98). For example, in women, the predominant component of MetSyn is abdominal 
obesity (often measured as waistline circumference), whereas in men, the predominant 
component is hypertension (62). In both men and women, these two components occur most 
frequently in combination with low HDL cholesterol levels and elevated triglyceride levels 
to form the triad of factors used to define MetSyn. Additional components of the MetSyn 
and other obesity co-morbidities have also been found to exhibit substantial sex differences 
in both humans and mouse models, as reviewed below and summarized in Figure 1.
a. Plasma lipid levels
Dyslipidemia is a key component of the MetSyn and often occurs together with obesity. A 
widely held generalization regarding lipid levels and cardiovascular disease is that elevated 
levels of low density lipoproteins (LDL) are detrimental, whereas elevated high density 
lipoproteins (HDL) are beneficial (20). However, the reality is more complex than this. 
Recent work indicates that the context in which HDL levels occur (i.e., levels of LDL and 
triglycerides) influences the utility of HDL as a predictor of cardiovascular disease risk (9). 
Furthermore, specific subspecies of each of the lipoprotein classes appear to be more 
relevant to cardiovascular disease prediction than others. In the broadest terms, pre-
menopausal women are found to have higher levels of HDL cholesterol than men, and men 
have higher LDL cholesterol levels (11, 39, 43, 58, 75). Within the lipoprotein classes are 
subclasses that differ in size, lipid and protein composition, and potentially, function. An 
examination of the lipoprotein subclasses reveals that men tend to have a profile that 
includes several characteristics associated with cardiovascular disease risk (small LDL, 
small HDL, large very low density lipoproteins (VLDL)), whereas women are likely to 
likely to have higher concentrations of large HDL particles, which are associated with 
athero-protection (58).
It is clear that gonadal hormones (either directly or indirectly) influence the lipoprotein 
profile. Lipoprotein profiles are altered in women after menopause, and this can be partially 
reversed by exogenous hormone replacement therapy (11, 24, 29, 113). Androgen levels in 
men also appear to influence lipid levels and cardiovascular disease risk. Conflicting data 
exist, but at least some data indicate that androgen action is not likely the major determinant 
of LDL cholesterol levels (54, 81, 113, 115). Much work remains to be done to determine 
the relevance of specific lipid profile characteristics on cardiovascular disease risk in men 
and women. Understanding these mechanisms is important, however, as it will inform 
therapeutic approaches and management of cardiovascular disease.
Toward understanding basic mechanisms that influence lipid levels differentially in males 
and females, animal models may provide some insight. For example, a study performed in 
Link and Reue Page 8













the Four Core Genotype mouse model identified some aspects of lipid levels that are 
determined predominantly by presence of male or female gonads, and other aspects that are 
determined by the presence of 2 X chromosomes (as found in XX animals) compared to 1 X 
chromosome (as found in XY animals) (70). While humans transport the majority of 
cholesterol in the form of LDL particles, mice transport the majority of cholesterol in the 
form of HDL particles. However, when fed a cholesterol-enriched diet, mice increase LDL 
cholesterol levels substantially to levels resembling humans. Studies of lipid levels in mice 
of the Four Core Genotypes (XX female, XX male, XY female, and XY male mice) revealed 
that under basal conditions in which the mice were fed a chow diet, plasma HDL cholesterol 
levels were higher in animals with XX vs. XY chromosome complement, and also in mice 
with male vs. female gonads (Figure 5). LDL cholesterol levels, which were only about one-
fifth of HDL levels on the chow diet, were similar across the four genotypes, whereas 
triglyceride and free fatty acid levels were higher in males compared to females, regardless 
of the sex chromosome complement. To determine the contribution of acute-acting gonadal 
hormones, adult mice were gonadectomized. This led to a loss of male/female differences, 
and accentuated the effects of XX chromosome complement on promoting higher HDL 
cholesterol and free fatty acid levels. When fed a cholesterol-enriched diet, LDL cholesterol 
levels increased and were similar among the four genotypes. However, XX mice had higher 
levels of HDL cholesterol, whereas XY mice had higher levels of triglycerides and free fatty 
acids. Importantly, using a separate mouse model with XX, XXY and XY genotypes, it was 
demonstrated that HDL cholesterol levels are elevated in XX and XXY mice compared to 
XY mice, indicating that the presence of two X chromosomes, rather than absence of a Y 
chromosome, confers the high HDL phenotype (70). These results reveal that specific 
components of the lipid profile may be influenced independently by gonadal hormones 
and/or sex chromosomes, and that the underlying sex chromosome complement, rather than 
sex hormones, may be a key determinant of HDL cholesterol levels.
b. Glucose dysregulation
A common co-morbidity of obesity is impaired glucose homeostasis and insulin resistance. 
The standard measures of glucose homeostasis are determinations of fasting glucose levels 
or glucose tolerance, the latter measured as the kinetics of glucose clearance from the blood 
following an acute glucose load. Abnormal values for either of these traits may indicate 
impaired glucose metabolism, but the mechanisms underlying each are distinct. Indeed, only 
a minority of individuals with dysregulated glucose metabolism (about one-fourth) exhibit 
impairment in both fasting glucose and glucose tolerance (49). Elevated fasting glucose 
levels could result from inadequate levels of insulin secretion and/or impaired hepatic insulin 
sensitivity, leading to dysregulated glucose production by the liver. By contrast, impaired 
glucose tolerance is more likely a result of peripheral insulin resistance at the sites of post-
prandial glucose disposal, especially skeletal muscle. Notably, men are more likely to 
develop elevated fasting glucose levels, whereas women are more likely to develop impaired 
glucose tolerance, as shown in a meta-analysis of more than 20 studies from European and 
Asian populations (111). Assessments of insulin resistance show greater occurrence in men 
than women, even after adjusting for age and body mass index (42, 59, 80, 86). Key 
mechanisms that have been implicated include effects of gonadal hormone-dependent and -
independent sex differences in regional adipose tissue distribution, production of cytokines 
Link and Reue Page 9













and adipokines, hepatic gluconeogenesis and glycogenolysis, and glucose uptake by skeletal 
muscle (1, 86, 102). Sex differences in the mechanisms of dysglycemia raise a concern that 
diagnosis of MetSyn based on fasting glucose levels may not reliably identify women that 
have MetSyn and should undergo some intervention.
Sex differences in glucose metabolism have also been described in rodent models. In a 
screen of ~100 inbred mouse strains, Park et al. compared males and females for the 
development of insulin resistance as assessed by HOMA-IR after feeding a high fat/high 
carbohydrate diet (93). In nearly all strains, males were more prone to insulin resistance than 
females. HOMA-IR was correlated with total body fat and mesenteric fat pad weights in 
both males and females, but only females showed a strong correlation with additional 
visceral fat pads (gonadal and retroperitoneal fat depots). A set of three inbred mouse strains 
were studied with intact gonads or gonadectomy to determine the impact of gonadal 
hormones on the development of diet-induced insulin resistance. Ovariectomy improved 
insulin sensitivity in females of all three strains examined, but gonadectomy in male mice 
improved insulin sensitivity only in one of the three strains, demonstrating a hormone-gene 
interaction (93). Genetic association analyses identified distinct loci in males and females 
for plasma insulin and glucose levels (93), underscoring that mechanistic differences exist in 
the regulation of glucose metabolism between males and females.
Another approach to identify mechanisms underlying sex differences in the regulation of 
glucose homeostasis is the comparison of sex chromosome and gonadal sex contributions to 
glucose metabolism parameters. In most cases in mice and humans, increased adiposity 
correlates with insulin resistance. In the Four Core Genotypes mouse model, glucose and 
insulin levels were analyzed in mice that were gonadectomized to remove effects of acute 
gonadal hormones. As described in an earlier section, XX mice (with either male or female 
original gonads) gained more fat than XY mice (of either gonadal type) (21). Despite this, 
the XX mice had similar glucose and insulin levels and glucose tolerance as XY mice. The 
ability to maintain glucose homeostasis in XX mice despite higher body fat could indicate 
that compensatory changes occur in XX mice, as suggested by enhanced fatty acid oxidation 
gene expression profiles in muscle and liver (21). When animals are made obese by feeding 
a high fat-high carbohydrate diet, the XX mice appear to be more prone to insulin resistance 
(Figure 5), as they have two-fold higher plasma insulin levels to maintain similar plasma 
glucose levels as XY mice (21). This effect may be secondary to increased obesity in XX 
mice.
c. Non-alcoholic fatty liver
A common co-morbidity of obesity and insulin resistance is nonalcoholic fatty liver disease 
(NAFLD). This condition is characterized by the accumulation of neutral lipids in 
hepatocytes and represents the initial stage of a continuum of conditions that can progress to 
include severe inflammation (steatohepatitis), and further, to fibrosis and cirrhosis (2, 28). 
Data show increased cardiovascular disease mortality and overall mortality in individuals 
with NAFLD/steatohepatitis (34, 88), but it is difficult to disentangle this risk from that due 
to conditions that typically occur in tandem, such as obesity and MetSyn (120). Sex 
differences have been noted in the prevalence of NAFLD, but these vary depending on the 
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criteria used to define NAFLD, ethnicity, and other clinical characteristics of the subjects 
(91). In population-based studies, which may have less ascertainment bias than case-control 
studies, men have been found to have higher incidence of NAFLD than women (reviewed in 
68). In some, but not all cases, the greater occurrence of NAFLD in men remained after 
adjustment for body weight and insulin resistance (15, 25). Interestingly, in a study where 
individuals are segregated into lean and overweight/obese groups, lean women had a higher 
incidence of NAFLD than lean men (121). There may be distinct mechanistic etiologies for 
fatty liver that occurs in the context of obesity compared to that occurring in lean 
individuals.
As with most metabolic phenotypes discussed here, gonadal hormones likely contribute to 
differences in fatty liver development, either directly through estrogen and androgen 
receptor signaling, or indirectly through effects on adiposity, insulin resistance, etc. Studies 
in male rats that were gonadectomized and treated with estradiol or dihydrotestosterone 
showed that both of these hormones decreased lipid accumulation in the liver (124). 
Estradiol appeared to reduce fatty acid synthesis, and testosterone increased cholesterol 
synthesis, each in specific hepatic zones. Studies using the Four Core Genotypes mouse 
model indicate that gonad-independent mechanisms also influence fatty liver development. 
Mice that were gonadectomized as adults and then fed a high fat/high carbohydrate diet for 
12 weeks gained substantial body weight and fat, regardless of gonadal and chromosomal 
sex (21). Interestingly, only XX mice developed pronounced fatty liver with large 
triglyceride droplets, whereas XY mice accumulated much less triglyceride and only very 
small lipid droplets (Figure 5). The XX vs. XY effect occurred regardless of whether the 
original gonads were male or female, and occurred in the absence of gonadal secretions, 
indicating that gonad-independent sex differences are involved. However, although both XX 
and XY mice were obese, the XX mice had greater adiposity and hyperinsulinemia, making 
it difficult to determine whether the fatty liver in XX mice was independent or secondary to 
these other metabolic effects.
IV. The gut microbiome and sex differences in metabolic syndrome
In the past several years, there has been a surge in studies investigating the connection 
between the gut microbiome and human health. Perturbations in the microbial community 
are related to a wide range of diseases, including bowel disorders, autoimmune diseases, and 
metabolic disorders (27). Indeed, a direct effect of gut microbiota on obesity was elegantly 
demonstrated by transplanting gut microbiota from lean or obese mice into germ-free mice. 
Mice that received microbiota from diet-induced or genetically obese mice gained weight 
compared to recipients of microbiota from lean donors (109, 110). These findings suggest 
that gut flora have the capacity to dramatically influence host metabolism, including effects 
on energy acquisition and storage.
Although the field is still young, studies demonstrate that diet, sex, and genetic background 
may each influence the composition of the gut microflora, and that the microbial community 
in turn impacts hormone levels, immunity, and metabolic homeostasis in the host. Relevant 
to obesity, mice fed a high fat/high sucrose diet for 8 weeks dramatically changed their 
microbial makeup compared to chow fed mice, particularly the levels of Bacteroidetes and 
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Firmicutes (92). These changes were dependent on the specific mouse strain, indicating that 
genetic background influences the gut microbiota composition. Furthermore, some genera 
(Akkermansia, Lactococcus, and Allobaculum) were correlated with the gain in body fat due 
to diet, highlighting the connection of gut microbes with metabolic health. In addition to 
diet, the gut microbiota respond to the diurnal cycle, with fluctuations in major phyla such as 
Firmicutes, Bacteroidetes, and Verrucomicrobia (123). Feeding a high fat diet (61% calories 
from fat) for 8 weeks suppressed the diurnal fluctuations in microbial composition and 
reduced species, which may be detrimental to overall health (72). One hypothesis is that 
metabolites produced by the gut flora, including catabolized complex carbohydrates and bile 
acids, may signal to and alter host metabolism.
A recent study investigated the effects of sex on gut microbial communities (89). Of 89 
strains of mice examined, 7 strains had significant sex differences in abundance of microbial 
taxa. To determine how these sex differences were affected by nutritional excess, the authors 
examined male and female C57BL/6J, C3H/HeJ, and DBA/2J mice on a high fat/high 
sucrose diet for 8 weeks. They identified a sex-by-diet interaction in microbiota 
composition, suggesting that specific taxa respond to diet in a sex-dependent manner. For 
example, in DBA/2J mice, members of the Firmicutes phylum increased in females but 
decreased in males in response to high fat diet. In addition, gonadectomy revealed that 
circulating sex hormones regulate the gut microbiome in a strain- and diet-dependent 
manner.
While many factors influence microbial composition, the gut flora itself remarkably affects 
testosterone levels in both males and females (76). Germ-free females had higher levels of 
testosterone compared to females housed in specific pathogen-free facilities, while germ-
free males had reduced levels of testosterone compared to males housed under specific 
pathogen-free conditions. Perhaps most strikingly, transplantation of microbiota from adult 
male cecum to female weanlings resulted in a significant increase of testosterone at 7 and 14 
weeks of age (76). At 34 weeks of age, the microbial community reverted to a population 
resembling female gut flora, and testosterone changes were no longer apparent. The 
implications of this manipulation were reflected in protection of type 1 diabetes in nonobese 
diabetic (NOD) mice. Female mice that had received male cecal bacteria were protected 
from autoimmune destruction of pancreatic β cells, while those that had received female 
cecal bacteria were not. In addition, treatment of an androgen receptor antagonist abrogated 
the protective effects of male cecal bacteria, suggesting that the transfer-mediated enhanced 
testosterone levels were required for protection from type 1 diabetes (76). While these and 
other data showcase a critical role of the gut microbiome in regulating sex hormones and 
diabetes, future studies are needed to fully understand the underlying mechanisms (94).
Sex differences inherent in the host may also affect processing of metabolites generated by 
the gut microbiome. The hepatic enzyme flavin monooxygenase 3 (FMO3) is expressed over 
1000 times higher in females compared to males (114). FMO3 catalyzes the last step in the 
gut-flora-dependent metabolism of dietary phosphatidylcholine to trimethylamine N-oxide 
(TMAO), which is a significant contributor to atherosclerosis (65, 107, 114). Aortic lesion 
size was positively correlated with Fmo3 expression levels in Apoe−/− mice (114), and 
increased levels of TMAO were associated with thrombosis risk and with a 4-fold increased 
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mortality risk (101, 125). As more attention is focused on the impact of TMAO on 
cardiovascular disease risk, investigators should keep in mind the innate sex difference in 
TMAO levels and Fmo3 expression (105). Taken together, these studies indicate that 
complex relationships exist between sex, gut microbiota, and metabolic health, and 
underscore the importance of further mechanistic studies.
V. Future Perspectives
a. Increased emphasis on studying sex differences
Given that sex is one of the most profound biological determinants, it is unfortunate that it 
has not always received attention in studies of normo- and pathophysiology. Both pre-
clinical and clinical studies have traditionally focused on a single sex, and more often than 
not, this has been male (for examples, see 65, 69, 96). In the case of studies in experimental 
animals, a frequent justification was the notion that measurements made in male animals are 
less variable due to the hormonal fluctuations that occur during the female reproductive 
cycle. These concerns about variation in female rodent models have been refuted by analysis 
of published data involving behavior, electrophysiology, neurochemistry, histology and gene 
expression (10, 55). In recent years, the need for inclusion of both sexes in pre-clinical 
studies has been recognized and publicized (26, 32, 79, 100). It is hoped that these 
discussions will lead to a greater transparency in reporting the sexes used in pre-clinical 
studies, and increased inclusion of both sexes in both pre-clinical and clinical studies.
b. Tools to investigate sex differences
To enhance our understanding of sex differences, it is imperative to continue to develop 
experimental tools and strategies. As described here, tools such as mouse models that 
disentangle the genetic basis of sex determination from the gonadal type are valuable to 
begin to interrogate the mechanisms that underlie observed sex differences. Additionally, 
genetic manipulation of genes that respond to estrogens and androgens has provided insights 
into the many facets of gonadal hormone action in metabolism. In the future, greater 
exploitation of this technology to dissect tissue- and temporal-specific effects of estrogen 
and androgen signaling would be valuable. A resource to explore sex-specific gene 
expression in humans is now available in the form of the Genotype-Tissue Expression 
(GTEx) dataset (46). GTEx was developed primarily to identify loci that regulate gene 
expression in specific tissues. This has wide applicability in the interpretation of variants 
that are identified in GWAS studies and understanding disease mechanisms. GTEx includes 
RNA-seq data from approximately 50 human tissues, with hundreds of individual samples 
for many of the tissues. Fortunately, the architects of the GTEx project strived to include 
tissues from both men and women, such that these data will be useful to compare gene 
expression levels and signals for expression quantitative trait loci (eQTL) in men and 
women. These data have not yet been tapped extensively to analyze sex differences, but will 
undoubtedly be a valuable resource in the future. Along the same lines, it is hoped that more 
investigators will include the X chromosome in GWAS analyses, as tools are available for 
these analyses and recommendations have been made to promote their use (116).
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Despite decades of recognizing sex differences in obesity and cardiovascular disease, 
emphasis has seldom been placed on rigorously investigating regulation, interaction, and 
effects of sex differences on cellular mechanisms and whole-body physiology. In this review, 
we highlighted several key studies that investigate how sex affects obesity and its co-
morbidities, including insulin resistance, dyslipidemia, and fatty liver. For many years, sex 
differences were attributed to gonadal secretions. We and others have begun to reveal the sex 
chromosome complement as another determinant of sex differences in health and disease 
(Figure 5). However, gonadal hormones and sex chromosome complement are not mutually 
exclusive and do not act in isolation. Other factors, including X chromosome imprinting and 
inactivation, environmental stimulants, and the gut microbiome may interact with gonadal 
hormones and the sex chromosome complement to exert changes in gene expression and 
signaling pathways (Figure 6). Diet and circadian rhythms are two of the many external cues 
that influence metabolic homeostasis, and have been shown to interact with the gut 
microbiome. Although X chromosome imprinting and inactivation and other environmental 
factors were beyond the scope of this review, they may have important roles in determining 
sex differences in metabolism. There is undoubtedly a complex network that involves many 
components of sex differences and metabolism, which will be an exciting area of research in 
the future.
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Figure 1. Sex differences in metabolic syndrome (MetSyn) components
Risk factors for the MetSyn include visceral obesity, elevated triglyceride levels, low high 
density lipoprotein levels, hypertension, and elevated fasting glucose levels. Sex differences 
occur in most of these traits. Women tend to have increased fat mass proportional to their 
body weight, increased subcutaneous adipose tissue, and elevated HDL cholesterol levels. 
Men generally have greater proportional lean mass, increased visceral adipose tissue, and 
elevated plasma triglyceride levels. Cardiovascular disease incidence also differs by sex, 
with women having higher incidence of ischemic stroke, and men higher incidence of 
myocardial infarction.
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Figure 2. Genetic and hormonal components of sex
Male and female sex differences may result from genetic or hormonal components. Normal 
females and males differ in their sex chromosome complement of XX or XY, respectively. 
They also differ in the presence of ovarian or testicular gonadal hormones. In standard 
humans and mouse models, the genetic and gonadal contributions to sex differences cannot 
be easily distinguished.
Link and Reue Page 22













Figure 3. Distinction of gonadal and chromosomal contributions to sex differences using the Four 
Core Genotypes mouse model
The Four Core Genotypes mouse model breaks sex into gonadal type and sex chromosome 
complement as independent determinants. The four genotypes can be used to study the 
contribution of gonadal and chromosomal sex to traits of interest.
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Figure 4. Using the Four Core Genotypes mouse model to study sex differences
Studies with the Four Core Genotypes are performed in a 2 x 2 comparison, using gonadal 
type (ovaries vs. testes) and chromosomal type (XX vs. XY) as the categories. A comparison 
of XX vs. XY mice (on both gonadal backgrounds) allows detection of effects due to sex 
chromosome complement. A comparison of female vs. male mice (with both sex 
chromosome genotypes) allows detection of effects due to gonadal type.
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Figure 5. Sex chromosome complement confers sex differences in MetSyn traits
Studies using the Four Core Genotypes mouse model have revealed that sex differences in 
some traits associated with MetSyn are influenced by the sex chromosome complement. For 
example, XX mice, regardless of having ovaries or testes, have increased fat mass relative to 
body weight, are susceptible to fatty liver, and exhibit increased HDL cholesterol. XY mice 
have been shown to have greater inflammation in the central nervous system (33) and 
improved cardiac recovery after ischemia injury (67).
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Figure 6. Sex differences in metabolism are influenced by many factors
Two primary sex-biasing sources are the sex chromosome complement and gonadal 
hormones, which in turn are influenced by other factors. The white arrows represent 
mediators of regulation, including gene expression changes and altered protein signaling 
pathways. In addition to the number of X chromosomes and the presence of a Y 
chromosome, XX and XY cells differ by the occurrence of X chromosome inactivation 
(exclusively in XX cells) and by the parent-of-origin X chromosome imprinting (only XX 
cells have X chromosome imprints from both parents). The gut microbiome and 
environmental factors such as diet, pollutants, and circadian cycle may interact with the sex 
chromosome complement and gonadal hormones to affect metabolism differently between 
males and females.
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